Repaglinide is a therapeutic drug for diabetes. It is a non-sulfonylurea insulin-releasing agent. It was successfully developed by Boehringer Ingelheim, Germany. It was approved by the US FDA in December 1997 and listed in the US and European countries in 1998. Novo and Dragon are clinically used mainly in patients with type 2 diabetes (non-insulin dependent) who are unable to effectively control hyperglycemia by diet control, weight loss and exercise.
More About Repaglinide：
|Melting point||129-130.2 °C|
Use Of Repaglinide :
Antidiabetic drugs. A non-sulfonylurea oral hypoglycemic agent for the treatment of type 2 diabetes.
Package Of Repaglinide :
Storage:Stored in a closed, low temperature, heated to decompose into ammonia and acetic acid